Press type rivastigmine hydrogen tartrate oral solution administration device

Abstract

The utility model provides a pressing type rivastigmine hydrogen tartrate oral solution administration device which comprises a bottle body, a pressing device and a pressing device. The bottle cap seals the opening in the upper end of the bottle body, and an external threaded pipe is arranged on the bottle cap; the pressing pump head assembly is connected with the bottle cap, and the liquid inlet end of the pressing pump head assembly penetrates through the bottle cap and is located on the inner side of the bottle body; the pressing head is connected with the liquid outlet end of the pressing pump head assembly, a liquid outlet pipe is arranged on the side wall of the pressing head, and the liquid outlet pipe is communicated with the liquid outlet end of the pressing pump head assembly; and the limiting pipe is in threaded connection with the external threaded pipe, and the limiting pipe limits the pressing head. The device has the advantages that the limiting pipe is rotated according to the dosage, the pressing head is limited by the limiting pipe, and the accuracy of the dosage is improved by adjusting the stroke of the pressing head.

Description

Technical Field

[0001] This utility model belongs to the field of pharmaceutical packaging technology, and in particular relates to a press-type rivastigmine tartrate oral solution delivery device. Background Technology

[0002] Some solution medications, after being taken orally, are absorbed through peripheral blood circulation and can only reach the disease site after crossing the blood-brain barrier. When the dosage is small, it is difficult to control the dosage. Current press-type pill bottles cannot accurately adjust the dosage according to the individual's disease progression. Using a syringe to draw out a certain amount before taking the medication is inconvenient. Utility Model Content

[0003] In view of this, the present invention aims to provide a press-type rivastigmine bitartrate oral solution delivery device in order to solve at least one of the above-mentioned technical problems.

[0004] To achieve the above objectives, the technical solution of this utility model is implemented as follows:

[0005] A press-type rivastigmine bitartrate oral solution delivery device includes:

[0006] The bottle body has an opening at its upper end;

[0007] A bottle cap that closes the opening at the top of the bottle body, and the bottle cap is provided with an external threaded tube;

[0008] The press pump head assembly is connected to the bottle cap, and the liquid inlet end of the press pump head assembly passes through the bottle cap and is located inside the bottle body;

[0009] The pressing head is connected to the liquid outlet end of the pressing pump head assembly. The pressing head has a liquid outlet pipe on its side wall, which is connected to the liquid outlet end of the pressing pump head assembly.

[0010] A limiting tube is threadedly connected to an external threaded pipe, and the limiting tube limits the movement of the pressing head.

[0011] Furthermore, the outer wall of the externally threaded tube is provided with a flat surface, and the flat surface is provided with scale markings arranged along the axis of the externally threaded tube.

[0012] Furthermore, the axis of the liquid outlet tube is set perpendicular to the axis of the pressing head;

[0013] The bottle body also includes an extension tube, one end of which is provided with a connector. The connector has an installation hole corresponding to the liquid outlet tube. The extension tube communicates with the installation hole. The axis of the installation hole is perpendicular to the axis of the extension tube. The liquid outlet tube is located inside the installation hole. The liquid outlet tube is interference-fitted with the connector.

[0014] Furthermore, an installation tube is fixedly provided at the upper end of the bottle body, the installation tube has external threads on the outside, the bottle cap has internal threads on the inside, and the bottle cap is threadedly connected to the installation tube.

[0015] Furthermore, the press pump head assembly includes:

[0016] The sleeve has a first annular protrusion on the inner side of its lower end, and a first sealing ball on the upper end of the first annular protrusion. The diameter of the first sealing ball is larger than the inner diameter of the first annular protrusion.

[0017] A piston ring is installed inside the sleeve, and a first compression spring is provided between the piston ring and the first annular boss.

[0018] A piston tube is installed inside the piston ring. A second compression spring is provided between the lower end of the piston tube and the first annular boss. A second annular boss is provided on the outer side of the upper end of the piston tube. The outer diameter of the second annular boss is smaller than the outer diameter of the piston ring.

[0019] A connecting tube, wherein the sleeve is installed on the inner side of the connecting tube, the connecting tube is fixedly connected to the bottle cap, the connecting tube passes through the bottle cap, and a third annular boss is fixedly provided on the inner side of the upper end of the connecting tube. The inner diameter of the third annular boss is smaller than the outer diameter of the piston ring and larger than the outer diameter of the second annular boss.

[0020] A limiting ring is installed at the lower end of the piston tube, with the lower end of the piston ring facing the limiting tube for limiting.

[0021] Furthermore, the sleeve is provided with a riser, the inner diameter of which is larger than the diameter of the first sealing ball. A guide hole is provided on the side wall of the riser. The upper end of the riser is closed, and an installation ring is provided on the outer side of the lower end of the riser. The installation ring is installed between the first compression spring and the first annular boss.

[0022] Furthermore, a guide tube is fixedly provided at the lower end of the piston tube, and a guide rod is fixedly provided at the upper end of the riser tube, with the guide rod installed on the inner side of the guide tube;

[0023] The second compression spring is installed on the outside of the guide tube and is located between the riser tube and the piston tube.

[0024] Furthermore, a flow guide hole 2 is provided on the lower end sidewall of the piston tube.

[0025] Furthermore, the pressing head has an installation groove, and the installation groove is provided with an installation post. The installation post has three through holes connected sequentially from bottom to top. The diameter of the through hole two is smaller than that of the through hole one, and the diameter of the through hole two is smaller than that of the through hole three. The through hole three is provided with a second sealing ball. The diameter of the second sealing ball is larger than that of the through hole two, but smaller than that of the through hole three. The through hole three is connected to the liquid outlet pipe.

[0026] The second limiting boss of the piston tube is installed inside the through hole one.

[0027] Furthermore, a filter screen is provided between the mounting column and the bottom end of the mounting groove;

[0028] A flexible tube is provided at the lower end of the sleeve, with one end of the flexible tube connected to the lower end of the sleeve and the other end located at the bottom of the inner side of the bottle.

[0029] Compared with the prior art, the press-type rivastigmine bitartrate oral solution delivery device of this utility model has the following beneficial effects:

[0030] (1) The present invention provides a press-type rivastigmine tartrate oral solution delivery device. The limiting tube is rotated according to the dosage, and the limiting tube limits the pressing head. By adjusting the stroke of the pressing head, the accuracy of the dosage is improved.

[0031] (2) The present invention provides a press-type rivastigmine tartrate oral solution delivery device, wherein the extension tube connector is detachably connected to the dispensing tube, and the extension tube angle can be rotated according to the usage requirements to feed patients with difficulty swallowing.

[0032] (3) The press-type rivastigmine tartrate oral solution delivery device of this utility model has a second compression spring and a first compression spring, which allows the piston tube to have two strokes. During the first stroke, the diameter of the piston tube is small, and less liquid is sprayed for the same distance, which facilitates precise control of the dosage. When the piston tube continues to move downward, the second annular boss pushes the piston ring to move. The diameter of the piston ring is large, and more liquid is sprayed for the same distance. The stroke of the piston rod can be reduced to complete the spraying of a larger dosage, which improves the convenience of drug delivery. Attached Figure Description

[0033] The accompanying drawings, which form part of this utility model, are used to provide a further understanding of the utility model. The illustrative embodiments of the utility model and their descriptions are used to explain the utility model and do not constitute an undue limitation of the utility model. In the drawings:

[0034] Figure 1 This is a three-dimensional structural diagram of the medicine bottle described in an embodiment of the present utility model;

[0035] Figure 2This is a schematic diagram of the three-dimensional structure of the bottle body according to an embodiment of the present utility model;

[0036] Figure 3 This is a three-dimensional structural diagram of the pressing head described in an embodiment of the present utility model;

[0037] Figure 4 This is a schematic diagram of the three-dimensional structure of the riser as described in an embodiment of the present utility model;

[0038] Figure 5 This is a three-dimensional structural diagram of the piston tube according to an embodiment of the present utility model;

[0039] Figure 6 This is a schematic diagram of the three-dimensional structure of the bottle cap according to an embodiment of the present utility model;

[0040] Figure 7 This is a schematic diagram of the cross-sectional structure of the medicine bottle according to an embodiment of the present invention;

[0041] Figure 8 As described in the embodiments of this utility model Figure 7 Schematic diagram of the three-dimensional structure at point A in the middle;

[0042] Figure 9 As described in the embodiments of this utility model Figure 7 Schematic diagram of the three-dimensional structure at point B;

[0043] Figure 10 This is a schematic cross-sectional view of the mounting column according to an embodiment of the present invention.

[0044] Explanation of reference numerals in the attached figures:

[0045] 1. Bottle body; 2. Bottle cap; 3. Pressing head; 4. Extension tube; 5. Hose; 6. Limiting tube; 7. Stand tube; 8. Second compression spring; 9. Piston tube; 10. First compression spring; 11. Mounting post; 12. Filter screen; 13. Second sealing ball; 14. First sealing ball; 15. Sleeve; 16. Piston ring; 17. Connecting tube; 18. Limiting ring; 101. Mounting tube; 201. External threaded tube; 202. Scale marking; 301. Discharge tube; 401. Connecting seat; 701. Mounting ring; 702. Guide rod; 703. Flow guide hole one; 901. Flow guide hole two; 902. Second annular boss; 903. Guide tube; 1101. Through hole one; 1102. Through hole two; 1103. Through hole three. Detailed Implementation

[0046] It should be noted that, unless otherwise specified, the embodiments and features described in these embodiments can be combined with each other.

[0047] In the description of this utility model, it should be understood that the terms "center," "longitudinal," "lateral," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," and "outer," etc., indicating orientation or positional relationships based on the orientation or positional relationships shown in the accompanying drawings, are only for the convenience of describing this utility model and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation, and therefore should not be construed as a limitation of this utility model. Furthermore, the terms "first," "second," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Thus, features defined with "first," "second," etc., may explicitly or implicitly include one or more of that feature. In the description of this utility model, unless otherwise stated, "a plurality of" means two or more.

[0048] In the description of this utility model, it should be noted that, unless otherwise explicitly specified and limited, the terms "installation," "connection," and "joining" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; and they can refer to the internal connection of two components. Those skilled in the art can understand the specific meaning of the above terms in this utility model based on the specific circumstances.

[0049] The present invention will now be described in detail with reference to the accompanying drawings and embodiments.

[0050] like Figures 1 to 10 As shown, a press-type rivastigmine bitartrate oral solution delivery device includes:

[0051] Bottle body 1, with an opening at the upper end; bottle cap 2, which closes the opening at the upper end of bottle body 1, and has an external threaded tube 201; a press pump head assembly, which is connected to the bottle cap 2, with the inlet end of the press pump head assembly penetrating the bottle cap 2 and located inside the bottle body 1; a press head 3, which is connected to the outlet end of the press pump head assembly, and has an outlet tube 301 on its side wall, which communicates with the outlet end of the press pump head assembly; and a limiting tube 6, which is threadedly connected to the external threaded tube 201, and limits the press head 3.

[0052] The outer wall of the external threaded tube 201 has a flat surface, and the flat surface has a scale mark 202 set along the axis of the external threaded tube 201. The scale mark 202 makes it easy to observe and set the liquid output.

[0053] The axis of the dispensing tube 301 is perpendicular to the axis of the pressing head 3. The bottle body 1 also includes an extension tube 4, one end of which is provided with a connecting seat 401. The connecting seat 401 has a mounting hole corresponding to the dispensing tube 301. The extension tube 4 communicates with the mounting hole, and the axis of the mounting hole is perpendicular to the axis of the extension tube 4. The dispensing tube 301 is located inside the mounting hole, and the dispensing tube 301 is press-fitted to the connecting seat 401. The connecting seat 401 of the extension tube 4 is detachably connected to the dispensing tube 301. The extension tube 4 can be rotated according to usage needs to feed patients with difficulty swallowing.

[0054] The upper end of the bottle body 1 is fixed with an installation tube 101. The outer side of the installation tube 101 has an external thread, and the inner side of the bottle cap 2 has an internal thread. The bottle cap 2 is threadedly connected to the installation tube 101.

[0055] The pump head assembly includes: a sleeve 15, with a first annular boss on the inner side of the lower end of the sleeve 15, and a first sealing ball 14 on the upper end of the first annular boss, the diameter of the first sealing ball 14 being larger than the inner diameter of the first annular boss; a piston ring 16, installed inside the sleeve 15, with a first sealing ring between the outer wall of the piston ring 16 and the inner side of the sleeve 15, and a first compression spring 10 between the piston ring 16 and the first annular boss; and a piston tube 9, installed inside the piston ring 16, with a second sealing ring between the inner wall of the piston ring 16 and the outer side of the piston tube 9, and a second compression spring 10 between the lower end of the piston tube 9 and the first annular boss. Spring 8, piston tube 9 has a second annular boss 902 on the outer side of the upper end, the outer diameter of the second annular boss 902 is smaller than the outer diameter of the piston ring 16; connecting tube 17, sleeve 15 is installed on the inner side of connecting tube 17, sleeve 15 and connecting tube 17 are interference-fitted and threaded, connecting tube 17 is interference-fitted or welded to bottle cap 2, connecting tube 17 passes through bottle cap 2, a third annular boss is fixed on the inner side of the upper end of connecting tube 17, the inner diameter of the third annular boss is smaller than the outer diameter of piston ring 16 and larger than the outer diameter of the second annular boss 902; limiting ring 18, limiting ring 18 is installed at the lower end of piston tube 9, the lower end of piston ring 16 faces the limiting tube 6 for limiting.

[0056] The inner diameter of the riser 7 is larger than the diameter of the first sealing ball 14. A guide hole is provided on the side wall of the riser 7. The upper end of the riser 7 is closed, and an installation ring 701 is provided on the outer side of the lower end of the riser 7. The installation ring 701 is installed between the first compression spring 10 and the first annular boss. The riser 7 limits the first sealing ball 14, enabling the first sealing ball 14 to quickly seal the first annular boss.

[0057] A guide tube 903 is fixedly installed at the lower end of the piston tube 9, and a guide rod 702 is fixedly installed at the upper end of the riser tube 7. The guide rod 702 is installed inside the guide tube 903. The second compression spring 8 is installed outside the guide tube 903 and is located between the riser tube 7 and the piston tube 9. The cooperation between the guide rod 702 and the guide tube 903 guides the movement of the piston tube 9, making its movement more stable, and also limits the second compression, preventing it from disengaging from the guide tube 903. A flow guide hole is opened on the lower side wall of the piston tube 9.

[0058] The pressing head 3 has a mounting groove, and a mounting post is provided in the mounting groove. From bottom to top, the mounting post has three interconnected through holes: a first through hole 1101, a second through hole 1102, and a third through hole 1103. The diameter of the second through hole 1102 is smaller than that of the first through hole 1101, and the diameter of the third through hole 1103 is smaller than that of the third through hole 1103. A second sealing ball 13 is provided in the third through hole 1103. The diameter of the second sealing ball 13 is larger than that of the second through hole 1102 but smaller than that of the third through hole 1103. The third through hole 1103 is connected to the liquid outlet pipe 301. The second limiting boss of the piston tube 9 is installed inside the first through hole 1101. The mounting post can be threaded into the inner side of the mounting groove or interference-fitted into the inner side of the mounting groove.

[0059] A filter screen 12 is provided between the bottom of the mounting post and the mounting groove; the filter screen 12 not only serves to limit the second bee ball, but also filters the medicine liquid. A flexible tube 5 is provided at the lower end of the sleeve 15, one end of which is connected to the lower end of the sleeve 15, and the other end is located at the bottom of the inner side of the bottle body 1. The flexible tube 5 is interference-fitted to the lower end of the sleeve 15.

[0060] Cholinesterases are a class of glycoproteins, mainly comprising acetylcholinesterase (true cholinesterase) and butyrylcholinesterase (pseudocholinesterase). They are primarily found in the synaptic cleft of cholinergic nerve endings or within neurons, and are widely involved in the regulation of physiological functions, including regulating nerve conduction and participating in memory formation. In the peripheral nervous system, cholinesterases mainly participate in the regulation and transmission of nerve conduction in motor neurons, sympathetic nerves, and parasympathetic nerves, modulating neurotransmitters between neurons. In the central nervous system, cholinesterases primarily coordinate brain function and the delivery of memory and emotions. Cholinesterase inhibitors, such as donepezil and rivastigmine, are mainly used in the central nervous system for the treatment of neurodegenerative diseases.

[0061] Rosvastin, with its dual inhibitory effects on acetylcholinesterase and butyrylcholinesterase, is a first-line recommended treatment for mild to moderate Alzheimer's disease. Alzheimer's disease originates in the central nervous system, and drugs treating central nervous system diseases require sufficient exposure in the brain to be effective. However, existing cholinesterase inhibitors for Alzheimer's, including rivastigmine, are available in four forms: oral solutions, tablets, capsules, and transdermal patches. All four types require absorption through peripheral blood circulation and crossing the blood-brain barrier to reach the disease site.

[0062] Among them, rivastigmine bitartrate oral solution has been launched overseas, with a specification of 2mg / ml. The starting dose is 1.5mg (0.75ml), which is gradually increased to 3mg (1.5ml), 4.5mg (2.25ml), and 6mg (3ml).

[0063] Bottle 1 contains rivastigmine bitartrate oral solution, prepared from raw materials including the following components: rivastigmine bitartrate, pH adjuster, flavoring agent, preservative, coloring agent, and water; the concentrations of each component in the rivastigmine bitartrate oral solution are as follows: rivastigmine bitartrate 0.5 mg / ml to 10 mg / ml, flavoring agent 0.05 mg / ml to 10 mg / ml, preservative 0.05 mg / ml to 2.5 mg / ml, coloring agent 0.05 mg / ml to 2.5 mg / ml, and an appropriate amount of pH adjuster to make the pH of the rivastigmine bitartrate oral solution 3.0-5.0.

[0064] Each 100ml of rivastigmine bitartrate oral solution contains:

[0065] Cabavirin bitartrate 50-1000 mg;

[0066] The acid-base regulators citric acid and sodium citrate are used in amounts that bring the pH of the resulting solution to the range of 3.0 to 5.0.

[0067] Flavoring agent, in the amount of 0.5–1000 mg;

[0068] Preservatives, in amounts of 0.5–250 mg;

[0069] Colorant, in an amount of 0.5–250 mg.

[0070] Add water, as needed, to a total of 100ml.

[0071] The amount of rivastigmine bitartrate in each 100ml is 0.5-10mg.

[0072] The amount of rivastigmine tartrate per 100ml is 0.5mg, 1.0mg, 1.5mg, 2.0mg, 2.5mg, 3.0mg, 3.5mg, 4.0mg, 4.5mg, 5.0mg, 6.0mg, 7.0mg, 8.0mg, 9.0mg, or 10mg.

[0073] The flavoring agents are selected from: sucrose, fructose, sorbitol, sodium saccharin, steviol glycosides, sucralose, aspartame, sucralose, flavorings and combinations thereof.

[0074] The preservatives are selected from: benzoic acid, sodium benzoate, methyl benzoate, ethyl benzoate, propyl benzoate, butyl benzoate, chlorobutanol, benzyl alcohol, and combinations thereof.

[0075] The drug delivery device delivers 0.75 ml of medication per dose. The delivery device is selected from single-dose packaging of 0.75 ml, fixed 0.75 ml spray device, fixed 0.75 ml metering pump device, and fixed 0.75 ml press pump device.

[0076] After being stored at 40°C in the dark for 6 months, the content of active ingredients in the rivastigmine bitartrate oral solution remained above 95% of the initial content.

[0077] After being stored at 40°C in the dark for 6 months, the total related substances of rivastigmine bitartrate oral solution increased by no more than 10%.

[0078] The method for preparing rivastigmine bitartrate oral solution includes the following steps: (1) adding rivastigmine bitartrate, flavoring agent, preservative and optional other excipients to 80% of the prescribed amount of water and stirring to dissolve; (2) adding an acid-base adjuster to the resulting solution and monitoring the pH value of the solution to reach the pH value range specified in the prescription; (3) adding water to the full volume, checking the pH value of the solution, and adding an acid-base adjuster if necessary to reach the pH value range specified in the prescription.

[0079] Work process:

[0080] The limiting tube 6 is rotated according to the dosage, and the limiting tube 6 limits the pressing head 3. By adjusting the stroke of the pressing head 3, the accuracy of the dosage is improved.

[0081] When the press head 3 is pressed down, the piston tube 9 moves downward, the liquid pressure inside the sleeve 15 increases, the first sealing ball 14 moves downward to seal the first annular boss, and the second sealing ball 13 moves upward. The liquid inside the sleeve 15 flows out through the piston tube 9 and the outlet tube 301. When the press head 3 is released, under the elastic force of the second compression spring 8 and the first compression spring 10, the piston tube 9 moves upward, the liquid pressure inside the sleeve 15 decreases, the first sealing ball 14 moves upward, and the second sealing ball 13 moves downward to seal the through hole 1102. The liquid inside the bottle 1 enters the inside of the sleeve 15 through the hose 5 and the inside of the first annular boss.

[0082] The second compression spring 8 and the first compression spring 10 allow the piston tube 9 to have two strokes. During the first stroke, the diameter of the piston tube 9 is small, and less liquid is sprayed when it moves the same distance, which facilitates precise control of the dosage. During the second stroke, as the piston tube 9 continues to move downward, the second annular boss 902 pushes the piston ring 16 to move. The diameter of the piston ring 16 is large, and more liquid is sprayed when it moves the same distance. This reduces the stroke of the piston rod, allowing for the spraying of a larger dosage and improving the convenience of drug administration.

[0083] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of this utility model, and not to limit it. Although the utility model has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of this utility model, and they should all be covered within the scope of the claims and specification of this utility model.

[0084] The above description is only a preferred embodiment of the present utility model and is not intended to limit the present utility model. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present utility model should be included within the protection scope of the present utility model.

Claims

1. A press-type rivastigmine bitartrate oral solution delivery device, characterized in that, include: Bottle body (1), the upper end of the bottle body (1) is provided with an opening; Bottle cap (2), the bottle cap (2) closes the opening at the upper end of the bottle body (1), and the bottle cap (2) is provided with an external thread tube (201); The press pump head assembly is connected to the bottle cap (2), and the liquid inlet end of the press pump head assembly passes through the bottle cap (2) and is located inside the bottle body (1). Press head (3), press head (3) is connected to the liquid outlet end of press pump head assembly, and the side wall of press head (3) is provided with liquid outlet pipe (301), and the liquid outlet pipe (301) is connected to the liquid outlet end of press pump head assembly; The limiting tube (6) is threadedly connected to the external threaded tube (201), and the limiting tube (6) limits the pressing head (3).

2. The press-type rivastigmine bitartrate oral solution delivery device according to claim 1, characterized in that: The outer wall of the externally threaded tube (201) is provided with a flat surface, and the flat surface is provided with scale markings (202) arranged along the axis of the externally threaded tube (201).

3. The press-type rivastigmine bitartrate oral solution delivery device according to claim 1, characterized in that: The axis of the liquid outlet pipe (301) is set perpendicular to the axis of the pressing head (3); The bottle body (1) also includes an extension tube (4), one end of which is provided with a connecting seat (401). The connecting seat (401) has an installation hole corresponding to the liquid outlet tube (301). The extension tube (4) communicates with the installation hole. The axis of the installation hole is perpendicular to the axis of the extension tube (4). The liquid outlet tube (301) is located inside the installation hole. The liquid outlet tube (301) is interference-fitted with the connecting seat (401).

4. The press-type rivastigmine bitartrate oral solution delivery device according to claim 1, characterized in that: The upper end of the bottle body (1) is fixed with an installation tube (101), the outer side of the installation tube (101) is threaded, the inner side of the bottle cap (2) is threaded, and the bottle cap (2) is threadedly connected to the installation tube (101).

5. A press-type rivastigmine bitartrate oral solution delivery device according to claim 1, characterized in that... The press pump head assembly includes: The sleeve (15) has a first annular protrusion on the inner side of its lower end, and a first sealing ball (14) is provided on the upper end of the first annular protrusion. The diameter of the first sealing ball (14) is greater than the inner diameter of the first annular protrusion. Piston ring (16), the piston ring (16) is installed inside the sleeve (15), and a first compression spring (10) is provided between the piston ring (16) and the first annular boss; Piston tube (9), the piston tube (9) is installed inside the piston ring (16), a second compression spring (8) is provided between the lower end of the piston tube (9) and the first annular boss, and a second annular boss (902) is provided on the outer side of the upper end of the piston tube (9), the outer diameter of the second annular boss (902) is smaller than the outer diameter of the piston ring (16); Connecting tube (17), the sleeve (15) is installed on the inner side of the connecting tube (17), the connecting tube (17) is fixedly connected to the bottle cap (2), the connecting tube (17) passes through the bottle cap (2), a third annular boss is fixedly provided on the inner side of the upper end of the connecting tube (17), the inner diameter of the third annular boss is smaller than the outer diameter of the piston ring (16) and larger than the outer diameter of the second annular boss (902); A limiting ring (18) is installed at the lower end of the piston tube (9), and the lower end of the piston ring (16) faces the limiting tube (6) for limiting.

6. The press-type rivastigmine bitartrate oral solution delivery device according to claim 5, characterized in that: The sleeve (15) is provided with a riser (7), the inner diameter of the riser (7) is larger than the diameter of the first sealing ball (14), the riser (7) is provided with a guide hole on the side wall, the upper end of the riser (7) is closed, and the lower end of the riser (7) is provided with an installation ring (701), which is installed between the first compression spring (10) and the first annular boss.

7. A press-type rivastigmine bitartrate oral solution delivery device according to claim 6, characterized in that: The lower end of the piston tube (9) is fixedly provided with a guide tube (903), and the upper end of the riser tube (7) is fixedly provided with a guide rod (702). The guide rod (702) is installed on the inner side of the guide tube (903). The second compression spring (8) is installed on the outside of the guide tube (903) and is located between the riser tube (7) and the piston tube (9).

8. A press-type rivastigmine bitartrate oral solution delivery device according to claim 6, characterized in that: The piston tube (9) has a flow guide hole 2 on the lower end side wall.

9. A press-type rivastigmine bitartrate oral solution delivery device according to claim 5, characterized in that: The pressing head (3) has an installation groove, and an installation column is provided in the installation groove. The installation column has through holes 1 (1101), 2 (1102), and 3 (1103) connected sequentially from bottom to top. The diameter of through hole 2 (1102) is smaller than that of through hole 1 (1101), and the diameter of through hole 2 (1102) is smaller than that of through hole 3 (1103). A second sealing ball (13) is provided in through hole 3 (1103). The diameter of the second sealing ball (13) is larger than that of through hole 2 (1102) and smaller than that of through hole 3 (1103). Through hole 3 (1103) is connected to the liquid outlet pipe (301). The second annular boss (902) of the piston tube (9) is installed inside the through hole (1101).

10. A press-type rivastigmine bitartrate oral solution delivery device according to claim 9, characterized in that: A filter screen (12) is provided between the bottom of the mounting column and the mounting groove; A flexible tube (5) is provided at the lower end of the sleeve (15). One end of the flexible tube (5) is connected to the lower end of the sleeve (15), and the other end is located at the bottom of the inner side of the bottle body (1).

Images